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data also suggest that permanent alopecia can be seen with non-
busulfan containing regimens. One important observation was pa-
tients usually accept permanent alopecia as the price for the cure and
ﬁnd ways to hide it unless they are questioned about. This may be
responsible for underestimation of the true incidence of permanent
alopecia after HDC. Our ﬁndings may also have medico legal and
psychosocial implications that need to be taken into consideration
when consenting patients for HSCT.
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NO EVIDENCE FOR INCREASED TRANSPLANT RELATED TOXICITY IN
PH CHRONIC MYELOGENOUS LEUKEMIA (CML) AND ACUTE LYM-
PHOBLASTIC LEUKEMIA (ALL) WITH PRIOR EXPOSURE TO DASATINIB
Leiba, M.1, Shimoni, A.1, Guilhot, F.2, Martineau, G.2, Renaud, M.2,
Francois, S.2, Hardan, I.1, Nagler, A.1 1Chaim Sheba Medical Center,
Tel Hashomer, Israel; 2Oncology Hematology and Cell Therapy CHU La
Miletrie, Poitiers, France.
SCT is frequently used as salvage or curative therapy in patients
(pts) with advanced CML or Ph ALL previously treated with Ima-
tinib.While one study showed higher incidence of GVHD, VOD and
TRM, most studies have demonstrated that Imatinib therapy prior to
SCT does not adversely affect SCT outcome. Dasatinib is a SRC/
ABL kinase inhibitor currently being used in pts with Imatinib-
resistant. Most of these pts will eventually undergo SCT, raising the
question of whether Dasatinib therapy may adversely affect SCT
outcome. We report eight pts: CML – 6 (CP1-4, low sokal score –3,
high sokal score –1, CP2-1, AP-1) and Ph ALL –2 who received
Dasatinib prior to alloSCT (n7) or autoSCT (n1). Donors were
matched siblings –4 or unrelated –2 or mismatch related (haploSCT)
–1. 5 were male and 3 female with a median age of 46.5 (16-56) years.
First line therapies included Hydroxyurea & Interferon or chemo-
therapy followed by Imatinib for the CP CML and advanced CML/
Ph ALL pts, respectively. All pts subsequently received Dasatinib
70mg x 2/day due to resistance to Imatinib, resulting in complete
hematological response in all, as well as complete (n5) or partial
cytogenetic response (CyR) (n2) prior to SCT. One pt did not
achieve CyR prior to SCT. The pts were conditioned with either a
myeloablative (n5) or a reduced intensity protocol (n3). GVHD
prophylaxis consisted of CSA and MTX (n6) or complete T-cell
depletion (n1). Pts received a mobilized peripheral blood stem cell
graft with 11.4–19.8 106 CD34 cells/ kg. The pt who underwent
autoSCTwas successfully mobilized (2 apheresis cycles yielding 5.7
106 CD34/kg). Dasatinib was stopped 6 days before mobilization.
All pts engrafted reaching ANC  0.5109/L on day 14 (11-21)
and PLT 20109/L on day 12.5 (11-17). Chimerism was 99.4 –
100%. Transplant related toxicities were minimal. Only 1 pt devel-
oped severe mucositis. No pt developed hyperbilirubinemia or VOD.
There was no increased risk of infections. Acute GVHD (Gr II) was
observed in only 1 pt, while 2 developed extensive chronic GVHD.
With a median followup of 8.5 (2-13) months, 6 pts are alive, 5 in CR,
while 2 died of disease progression. We may conclude that in pts
undergoing SCT following Dasatinib there is no evidence that Da-
satinib adversely affect post SCT outcome as no increased transplant
related organ toxicities, non-engraftment, GVHD or infections were
observed. Larger studies are obviously indicated to conﬁrm our pre-
liminary results.
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ONCE-DAILY ADMINISTRATION OF MODIFIED-RELEASE TACROLIMUS
CAPSULE (MR) FOR THE PROPHYLAXIS OF GRAFT-VERSUS-HOST-DIS-
EASE (GVHD) AFTER UNRELATED DONOR BONE MARROW TRANS-
PLANTATION (BMT)
Okamoto, S.1, Gondo, H.2, Imamura, M.3, Kodera, Y.4 1Keio University
Hospital, Tokyo, Japan; 2Saga Prefectural Hospital Koseikan, Saga,
Japan; 3Hokkaido University Hospital, Sapporo, Japan; 4Japanese Red
Cross Nagoya First Hospital, Nagoya, Japan.
The safety and efﬁcacy proﬁles of tacrolimus capsule, twice-daily
(BID) administration of Prograf® (PRG), in patients received al-
logeneic stem cell transplantation are well deﬁned. MR is an
extended-release formulation of tacrolimus which is administered
once-daily (QD). QD dosing regimen could improve compliance
and convenience while maintaining the potency of immune sup-
pression. Studies in renal and liver transplantation indicated that
the MR formulation given QD and PRG administered BID
showed a similar exposure (AUC0-24) and correlation between
AUC0-24 and Cmin.
We here report the efﬁcacy, safety and pharmacokinetics (PK) of
MR in patients who underwent allogeneic BMT from HLA-
matched unrelated donors. PRG was started as continuous i.v. at a
dose of 0.03mg/kg from 1 to 3 days before BMT, MTX was also
given on days 1, 3 and 6. The infusion of tacrolimus was switched
to QD oral administration of MR 38.0 days (24-87 days) after
BMT. The blood sampling for PK was collected 8-60 days after
administration of MR. A total of 20 patients received BMT, and 15
of them received MR. The diagnosis included AML (3), CML(3),
MDS (3), ML (2), ATL (1), CNL (1), Waldenstrom’s Macroglob-
ulinemia (1) and Myeloﬁbrosis (1). All 15 patients received TBI,
together with cyclophosphamide (13), or cytarabine (1), or mel-
phalan (1) as conditioning. Acute GVHD was graded according to
the modiﬁed Gluksberg grading system.
Before day 100 post-BMT, 7 of 15 (46.7%) patients developed
grade II-IV acute GVHD, and 3 (20.0%) developed grade III-IV
acute GVHD. Three patients developed grade II-IV acute GVHD
(2 grade II and 1 grade III) after conversion to MR. At one year
post-BMT, cumulative incidence of chronic GVHD was 51.0%,
and the cumulative overall survival rate was 93.3%. All adverse
drug reactions observed during the administration of MR were
already known as those of PRG. PK proﬁle of MR was evaluated in
13 patients. AUC0-24 and Cmin were 217.56100.01 ng.h/mL and
6.032.65 ng/mL, respectively. Co-efﬁciency between AUC0-24
and Cmin was highly correlated (r0.8679) as studies in renal and
liver transplantation.
These results suggest that QD administration of MR is effective
as an alternative to BID administration of PRG capsule for the
prophylaxis of acute and chronic GVHD in unrelated donor BMT.
Ongoing studies are aiming to evaluate the relapse and survival
rates over one year in BMT as well as the long-term beneﬁts of MR
in multiple types of organ transplantation.
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LATE-ONSET NONINFECTIOUS PULMONARY COMPLICATIONS AFTER
ALLOGENEIC BONE MARROW TRANSPLANTATION IN BRAZIL: INCI-
DENCE, CLINICAL FEATURES AND INFLUENCE OF TUBERCULOSIS
Fermino, F.A.1, Oliveira, J.S.R.1,2 1Universidade Federal de Sao Paulo,
Sao Paulo, Brazil; 2Hospital Santa Marcelina, Sa˜o Paulo, Brazil.
Despite advances in the management of bone marrow transplanta-
tion (BMT), pulmonary complications have been developed in 40-
60% of patients, inﬂuencing morbidity and mortalitality. Late-onset
noninfectious pulmonary complications (LONIPC) include a number
of different entities and an association with chronic graft-versus-host
disease (GVHD) has been noted for almost all of them. Among 253
patients who underwent allogeneic BMT at Universidade Federal de
Sa˜o Paulo andHospital SantaMarcelina, 159 of them survived at least
6 months, 16 (10%) fulﬁlled the diagnostic criteria of LONIPC.
There was a signiﬁcant association between pulmonary infectious
(p0,01), acute and chronic GVHD and the development of LO-
NIPC (p0,038 and 0,043, respectively). The frequency of Tubercu-
losis (Tb) among our patients was 3,7%. Two patients with previous
Tb fulﬁlled criteria for LONIPC. We believe that the pulmonary
symptoms and lung function tests presented by our patients can be
attributed to Tb sequelae. However, it was not possible to exclude
LONIPC since biopsy was not performed. On the other hand, it is
necessary to determine if in Brazil and other endemic areas of Tb, the
pulmonary biopsy can provide the correct diagnosis in similar cases. In
view of theses ﬁndings, we conclude that the LONIPC is an impor-
tant complication after allogenic BMT, chronic and acute GVHD is
signiﬁcantly associated with this complication and Tb sequelae can be
a differential diagnosis with LONIPCmainly in endemic areas. These
results have implications for the care of pacients who developed
respiratory symptoms after BMT.
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